Cat. No.: HY-14397

Indomethacin

(Synonyms: Indometacin)

83 Cited Publications

Customer Review

Based on 83 publication(s) in Google Scholar

Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research.

For research use only. We do not sell to patients.

Purity: 99.90%
CAS No.: 53-86-1
Formula: C₁₉H₁₆ClNO₄
Molecular Weight:357.79

Storage:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Indomethacin Chemical Structure

CAS No.: 53-86-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Induced Disease Models
Chemical Information
Publications (83)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Human COX-1

18 nM (IC₅₀, in CHO cells)

Human COX-2

26 nM (IC₅₀, in CHO cells)

SARS-CoV-2 Mpro

All COX Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	12 μM Compound: Indomethacin	Inhibition of human MRP1 in human 2008 cells Inhibition of human MRP1 in human 2008 cells	[PMID: 18707884]
2008	IC₅₀	12.6 μM Compound: indometacin	Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay	[PMID: 21354800]
A549	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20583750]
A549	IC₅₀	40.6 μM Compound: indomethacin	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis	[PMID: 22992107]
A549	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
Bel-7402	IC₅₀	>100 μM Compound: Indomethacin	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	>100 μM Compound: Indomethacin	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BJ	IC₅₀	>50 μM Compound: C	Cytotoxicity against human BJ cells after 72 hrs by luminescence assay Cytotoxicity against human BJ cells after 72 hrs by luminescence assay	[PMID: 20129783]
BV-2	IC₅₀	7.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24042007]
BV-2	IC₅₀	35.7 μM Compound: indomethacin	Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay	[PMID: 26348503]
BV-2	IC₅₀	34.5 μM Compound: Indomethacin	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 27120704]
BV-2	IC₅₀	19.51 μM Compound: Indomethacin	Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay	[PMID: 37530709]
BV-2	IC₅₀	15.2 μM Compound: Indomethacin	Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production	[PMID: 37683361]
BV-2	IC₅₀	55.44 μM Compound: Indomethacin	Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pretreated for 1 hr followed by LPS-stimulation and measured after 18 hrs by 2,3-diaminonaphthalene reagent based fluorescence analysis Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pretreated for 1 hr followed by LPS-stimulation and measured after 18 hrs by 2,3-diaminonaphthalene reagent based fluorescence analysis	[PMID: 37683361]
CHO	IC₅₀	0.018 μM Compound: Indomethacin	In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells	[PMID: 10576684]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells	[PMID: 10576684]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	Inhibition of PGE-2 production in CHO cells expressing human COX-2. Inhibition of PGE-2 production in CHO cells expressing human COX-2.	[PMID: 10576685]
CHO	IC₅₀	3 μM Compound: Indomethacin	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	[PMID: 10991954]
CHO	IC₅₀	25 μM Compound: 5	Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA	[PMID: 20503989]
CHO	IC₅₀	25 μM Compound: 2	Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA	[PMID: 21873070]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2 In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2	[PMID: 9873621]
CHO	IC₅₀	0.039 μM Compound: Indomethacin	Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1 Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1	10.1016/S0960-894X(96)00501-X
CHO	IC₅₀	0.049 μM Compound: Indomethacin	Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2 Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2	10.1016/S0960-894X(96)00501-X
CHO	IC₅₀	0.018 μM Compound: Indomethacin	In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1 In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1	10.1016/S0960-894X(96)00580-X
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2 In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2	10.1016/S0960-894X(96)00580-X
CHO	IC₅₀	0.018 μM Compound: Indomethacin	Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells	10.1016/S0960-894X(96)00582-3
CHO	IC₅₀	0.026 μM Compound: Indomethacin	Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells	10.1016/S0960-894X(96)00582-3
COS-7	IC₅₀	>1000 μM Compound: Indomethacin	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
CV-1	EC₅₀	50 μM Compound: Indomethacin	Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay	[PMID: 16643023]
DU-145	IC₅₀	>100 μM Compound: 4; Ind	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	IC₅₀	0.086 μg/mL Compound: Indomethacin	Hemolytic activity in human RBC assessed as membrane mortification by absorbance method Hemolytic activity in human RBC assessed as membrane mortification by absorbance method	[PMID: 29803359]
Erythrocyte	IC₅₀	40.04 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method	[PMID: 30108827]
Erythrocyte	IC₅₀	40 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method	[PMID: 30108882]
HCT-116	IC₅₀	136.8 μM Compound: INDO	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
HCT-116	EC₅₀	136.8 μM Compound: Indomethacin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	[PMID: 33569941]
HCT-15	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HEK293	IC₅₀	>50 μM Compound: C	Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay	[PMID: 20129783]
HEK293	IC₅₀	12 μM Compound: Indometacin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	140 μM Compound: Indometacin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	41 μM Compound: Indometacin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	>500 μM Compound: indomethacin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	50 μM Compound: Indomethacin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20583750]
HeLa	EC₅₀	0.14 nM Compound: 1, IMN	Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay	[PMID: 23432095]
HeLa	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
HepG2	IC₅₀	>50 μM Compound: C	Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay	[PMID: 20129783]
HT-29	IC₅₀	1052 μM Compound: Indomethacin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22940705]
HT-29	IC₅₀	312.6 μM Compound: INDO	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
HT-29	EC₅₀	312.6 μM Compound: Indomethacin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability	[PMID: 33569941]
HT-29	IC₅₀	>100 μM Compound: 4; Ind	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
J774	IC₅₀	0.002 μM Compound: Indomethacin	In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	0.009 μM Compound: Indomethacin	In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 24268542]
J774	IC₅₀	29.6 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 24268542]
J774.A1	IC₅₀	28.42 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent	[PMID: 23688954]
J774.A1	IC₅₀	28.56 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs	[PMID: 25140384]
K562	IC₅₀	190 μM Compound: Indomethacin	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
L02	IC₅₀	>100 μM Compound: Indomethacin	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
LNCaP	IC₅₀	>300 μM Compound: Indomethacin	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	238.4 μM Compound: INDO	Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
LNCaP	EC₅₀	238.4 μM Compound: Indomethacin	Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability	[PMID: 33569941]
Macrophage	IC₅₀	22 μM Compound: indomethacin	Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method	[PMID: 8988605]
Macrophage	IC₅₀	22 μmol Compound: indomethacin	Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method	[PMID: 8988605]
Mast cell	IC₅₀	250 μL Compound: Indomethecin	Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells	[PMID: 15270561]
Mast cell	IC₅₀	250 μM Compound: Indomethacin	Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells	[PMID: 20586436]
MCF7	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20583750]
MCF7	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
MCF7	IC₅₀	>100 μM Compound: 4; Ind	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MDA-MB-231	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20583750]
MDCK-II	IC₅₀	235 μM Compound: Indomethacin	Inhibition of human MRP2 expressed in dog MDCK2 cells Inhibition of human MRP2 expressed in dog MDCK2 cells	[PMID: 18707884]
MIA PaCa-2	IC₅₀	>100 mM Compound: Indomethacin	Cytotoxicity against human MIAPaCa2 cells Cytotoxicity against human MIAPaCa2 cells	[PMID: 23061607]
Mononuclear cell line	IC₅₀	0.3 μM Compound: Indomethacin	Inhibition of human PGE-2 production. Inhibition of human PGE-2 production.	[PMID: 1995900]
Neutrophil	IC₅₀	>40 μM Compound: indomethacin	Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release	[PMID: 17197180]
Neutrophil	IC₅₀	>40 μM Compound: indomethacin	Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation	[PMID: 17197180]
Neutrophil	IC₅₀	757.99 μg/mL Compound: indomethacin	Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production	[PMID: 19006373]
Neutrophil	IC₅₀	246.35 μM Compound: Indometacin	Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst	[PMID: 20576329]
Neutrophil	IC₅₀	32 μM Compound: Indomethacin	Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release	[PMID: 21316977]
Neutrophil	IC₅₀	38.3 μM Compound: Indomethacin	Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry	[PMID: 21316977]
Neutrophil	IC₅₀	31.98 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release	[PMID: 21848266]
Neutrophil	IC₅₀	38.32 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation	[PMID: 21848266]
Neutrophil	IC₅₀	271.212 μM Compound: Indomethacin	Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay	[PMID: 22437110]
PC-3	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20583750]
PC-3	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
Peritoneal macrophage	IC₅₀	147.5 μM Compound: Indomethacin	Anti-inflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as reduction in nitric oxide production Anti-inflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as reduction in nitric oxide production	[PMID: 37683361]
Platelet	IC₅₀	0.1 μM Compound: Indomethacin	Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	2.8 μM Compound: Indomethacin	Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	3.2 μM Compound: Indomethacin	Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	>100 μM Compound: indomethacin	Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation	[PMID: 17197180]
Platelet	IC₅₀	0.14 μM Compound: indomethacin	Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation	[PMID: 17197180]
Platelet	IC₅₀	1.62 μM Compound: Indomethacin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method	[PMID: 23639653]
Platelet	IC₅₀	0.21 μM Compound: Indomethacin	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method	[PMID: 8988600]
Raji	IC₅₀	>50 μM Compound: C	Cytotoxicity against human Raji cells after 72 hrs by luminescence assay Cytotoxicity against human Raji cells after 72 hrs by luminescence assay	[PMID: 20129783]
RAW	IC₅₀	15.37 μM Compound: indomethacin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA	[PMID: 21381754]
RAW	IC₅₀	23.47 μM Compound: indomethacin	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method	[PMID: 21381754]
RAW	IC₅₀	48.89 μM Compound: indomethacin	Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis	[PMID: 21381754]
RAW264.7	IC₅₀	52.8 nM Compound: Indomethacin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]
RAW264.7	IC₅₀	45.51 μM Compound: Indo	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method	[PMID: 19931461]
RAW264.7	IC₅₀	12.96 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay	[PMID: 20879743]
RAW264.7	IC₅₀	>100 μM Compound: indomethacin	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21381754]
RAW264.7	IC₅₀	>100 μM Compound: indomethacin	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21381754]
RAW264.7	IC₅₀	12.96 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry	[PMID: 21807513]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS	[PMID: 22633833]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS	[PMID: 22633833]
RAW264.7	IC₅₀	20 μM Compound: Indo	Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay	[PMID: 22633833]
RAW264.7	IC₅₀	148 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23566521]
RAW264.7	IC₅₀	12.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23755850]
RAW264.7	IC₅₀	16.67 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 24660966]
RAW264.7	IC₅₀	1.25 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24806310]
RAW264.7	IC₅₀	3.9 μM Compound: indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production	[PMID: 24960143]
RAW264.7	IC₅₀	15.8 μM Compound: Indomethacin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay	[PMID: 24963714]
RAW264.7	IC₅₀	18.7 μM Compound: Indomethacin	Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA	[PMID: 24963714]
RAW264.7	IC₅₀	1.25 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 25442320]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 25555141]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 25555141]
RAW264.7	IC₅₀	40.3 μM Compound: Indo	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method	[PMID: 25555141]
RAW264.7	IC₅₀	6.3 μM Compound: indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs	[PMID: 25621853]
RAW264.7	IC₅₀	14.1 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay	[PMID: 25821895]
RAW264.7	IC₅₀	10.7 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay	[PMID: 25881822]
RAW264.7	IC₅₀	4.5 μM Compound: Indo	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry	[PMID: 25881822]
RAW264.7	IC₅₀	9.2 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay	[PMID: 25881822]
RAW264.7	IC₅₀	42.6 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 25945867]
RAW264.7	IC₅₀	42.6 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay	[PMID: 26024020]
RAW264.7	IC₅₀	16.67 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 26615888]
RAW264.7	IC₅₀	12.5 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 26702644]
RAW264.7	IC₅₀	42.2 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay	[PMID: 26710212]
RAW264.7	IC₅₀	11.6 μM Compound: Indomethacin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 27276091]
RAW264.7	CC₅₀	>200 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27575472]
RAW264.7	IC₅₀	16.5 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay	[PMID: 27575472]
RAW264.7	IC₅₀	13.2 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis	[PMID: 27865705]
RAW264.7	IC₅₀	46.5 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RAW264.7	IC₅₀	33.6 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 28960979]
RAW264.7	IC₅₀	21.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay	[PMID: 29261312]
RAW264.7	IC₅₀	33.6 μM Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 30024153]
RAW264.7	IC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 30920218]
RAW264.7	IC₅₀	41 μM Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs	[PMID: 30920218]
RAW264.7	IC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against LPS-induced mouse RAW264.7 cells assessed as reduction in cell viability Cytotoxicity against LPS-induced mouse RAW264.7 cells assessed as reduction in cell viability	[PMID: 30925056]
RAW264.7	IC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability	[PMID: 30925056]
RAW264.7	IC₅₀	45.57 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay	[PMID: 30925056]
RAW264.7	CC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31365251]
RAW264.7	IC₅₀	38 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay	[PMID: 31365251]
RAW264.7	IC₅₀	62.9 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 31403786]
RAW264.7	IC₅₀	8.8 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay	[PMID: 31573805]
RAW264.7	IC₅₀	32.2 μM Compound: Indomethacin	Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay	[PMID: 32247751]
RAW264.7	IC₅₀	8.8 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay	[PMID: 32520548]
RAW264.7	IC₅₀	>10 μM Compound: Ind	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay	[PMID: 32823004]
RAW264.7	IC₅₀	>40 μM Compound: Ind	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay	[PMID: 32823004]
RAW264.7	IC₅₀	>40 μM Compound: Ind	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay	[PMID: 32823004]
RAW264.7	IC₅₀	24 μM Compound: Indomethacin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay	[PMID: 33160760]
RAW264.7	IC₅₀	26.2 μg/mL Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis	[PMID: 33422907]
RAW264.7	IC₅₀	26.3 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production	[PMID: 33422907]
RAW264.7	IC₅₀	32.3 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay	[PMID: 33422907]
RAW264.7	IC₅₀	16.7 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 33533247]
RAW264.7	IC₅₀	10.99 μM Compound: Indometacin	Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay	[PMID: 34352712]
RAW264.7	IC₅₀	40.7 μM Compound: INDO	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay	[PMID: 35175765]
RAW264.7	IC₅₀	42.3 μM Compound: Indometacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay	[PMID: 35512012]
RAW264.7	IC₅₀	34.28 μM Compound: Indomethacin	Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay	[PMID: 35660249]
RAW264.7	IC₅₀	34.49 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by griess reagent based assay	[PMID: 36450214]
RAW264.7	IC₅₀	0.62 μM Compound: Ind	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 36888988]
RAW264.7	IC₅₀	56.8 μM Compound: Indo	Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis	[PMID: 37224762]
RAW264.7	IC₅₀	17.64 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis	[PMID: 37683361]
RAW264.7	IC₅₀	8.5 μM Compound: Indomethacin	Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 37683361]
RAW264.7	CC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 2 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 2 hrs by MTT assay	[PMID: 38394380]
RAW264.7	IC₅₀	24 μM Compound: Indomethacin	Antiinflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 38394380]
RAW264.7	IC₅₀	37.5 μM Compound: Indomethacin	Inhibition of NO production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs by absorbance based assay Inhibition of NO production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs by absorbance based assay	[PMID: 39110498]
RAW264.7	IC₅₀	7.31 μM Compound: IND	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 23 hrs by Griess method Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 23 hrs by Griess method	[PMID: 39140047]
RBL-1	IC₅₀	>25 μM Compound: Indomethacin	Inhibitory activity against 5-lipoxygenase of RBL-1 cell line Inhibitory activity against 5-lipoxygenase of RBL-1 cell line	[PMID: 1507204]
RBL-1	IC₅₀	>100 μM Compound: 6	Inhibition of 5-lipoxygenase in intact RBL-1 cell line Inhibition of 5-lipoxygenase in intact RBL-1 cell line	[PMID: 2115586]
RBL-1	IC₅₀	0.5 μM Compound: 6	Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line	[PMID: 2115586]
RBL-1	IC₅₀	>>20 μM Compound: indomethacin	Inhibition of 5-lipoxygenase in rat RBL-1 cells Inhibition of 5-lipoxygenase in rat RBL-1 cells	[PMID: 2319562]
RBL-1	IC₅₀	0.0037 M Compound: Indomethacin	In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined	[PMID: 8254620]
RBL-1	IC₅₀	>100 μM Compound: Indomethacin	Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay	10.1016/S0960-894X(00)80396-0
RBL-1	IC₅₀	0.5 μM Compound: Indomethacin	Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay	10.1016/S0960-894X(00)80396-0
RBL-1	IC₅₀	>100 μM Compound: Ia	Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1) Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)	10.1016/S0960-894X(00)80450-3
RBL-1	IC₅₀	0.5 μM Compound: Ia	Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1) Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1)	10.1016/S0960-894X(00)80450-3
Sf21	IC₅₀	35.2 μM Compound: Indometacin	Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell	[PMID: 20974503]
Sf9	IC₅₀	12.4 μM Compound: 1	Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9) Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9)	[PMID: 11392547]
Sf9	IC₅₀	30 nM Compound: 1	Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9) Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9)	[PMID: 11392547]
Sf9	IC₅₀	7.81 μM Compound: Indomethacin	In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus	[PMID: 15026050]
Sf9	IC₅₀	0.75 μM Compound: 1, Indomethacin	Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis	[PMID: 21524587]
SK-LU-1	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
SW480	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
TERT-RPE1	IC₅₀	>40 μM Compound: 1	Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
THP-1	IC₅₀	>10 μM Compound: indomethacin	Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4 Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4	[PMID: 10737736]
THP-1	IC₅₀	>10 μM Compound: indomethacin	Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay	[PMID: 10737736]
THP-1	IC₅₀	0.0036 μM Compound: indomethacin	Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4 Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4	[PMID: 10737736]
THP-1	IC₅₀	>100 μM Compound: Indomethacin	In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells	[PMID: 10821716]
THP-1	IC₅₀	>10000 nM Compound: Indomethacin	Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	3.6 nM Compound: Indomethacin	Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	>10000 nM Compound: Indomethacin	Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	19.37 μM Compound: Indomethacin	Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis	[PMID: 37683361]
U-251	IC₅₀	20.45 μM Compound: Indomethacin	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
U-937	IC₅₀	0.02 μM Compound: Indomethacin	Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes. Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.	[PMID: 10576685]
U-937	IC₅₀	0.003 μM Compound: 1	Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma	[PMID: 11462976]
U-937	IC₅₀	0.002 μM Compound: 1 Indomethacin	In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells	[PMID: 12877584]
U-937	IC₅₀	0.02 μM Compound: Indomethacin	Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid	[PMID: 9873621]
VCaP	IC₅₀	136.9 μM Compound: INDO	Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
Vero C1008	CC₅₀	>100 μM Compound: 1; INM	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay	[PMID: 34534839]
Vero C1008	CC₅₀	>500 μM Compound: 1; INM	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay	[PMID: 34534839]

In Vitro

Indomethacin (Indometacin) (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro^[2].
Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC₅₀=2μM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
Concentration:

0, 20, 50, 100 and 150 μM
Incubation Time:

24 hours
Result:

Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.

Cell Viability Assay^[2]

Cell Line:

3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
Concentration:

0, 30 and 80 μM
Incubation Time:

24 hours
Result:

Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.

In Vivo

Animal Model:

Male Sprague-Dawley rats^[1]
Dosage:

0.01-10 mg/kg
Administration:

Oral administration; for 3 hours
Result:

Inhibited the carrageenan-induced rat paw oedema (ED₅₀=2.0 mg/kg) and hyperalgesia (ED₅₀=1.5 mg/kg) in a dose-dependent manner.

Animal Model:

Male C57BL/6J mice^[2]
Dosage:

10 mg/mL
Administration:

Oral administration; daily, for 29 days
Result:

Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Indomethacin can be used to induce gastric ulcer models. After oral administration, the drug is absorbed rapidly and completely, although there are interindividual and intraindividual variations. Typically, the plasma peak concentration (2-3 μg/mL) is reached within 1-2 hours. However, coadministration with food reduces and delays the peak concentration without affecting the total absorption. At therapeutic concentrations, 90% of Indomethacin is bound to albumin in the plasma^[4].

Induction of gastric ulceration^[5]^[6]

Background

Indomethacin can cause gastric ulceration by various mechanisms, including injury through inhibition of prostaglandin (PG) synthesis, reduction in local blood flow, regional irritation, and inhibition of tissue regeneration.

Specific Modeling Methods

Rat: albino Sprague-Dawley • male • adult (period: 2 weeks)
Administration: 100 mg/kg • p.o. • single dose

Note

(1) All animals fasted 24 h before drug administration.
(2) Indomethacin was dissolved in saline with 5% NaOH.

Modeling Indicators

Gastric tissue macroscopic alterations: Showed prominent mucosal folds and severe erosion, pronounced ulceration and bleeding foci in the gastric mucosa.
Histopathological changes: Showed severe erosion of the mucosa, reaching down to the lamina muscularis; observed hemorrhagic infiltration, edema in the submucosa, and severe hyperemia of the vessels.
Molecular changes: Showed intense Tnf-α expression.
Biochemical changes: Increased MDA, TOS levels, reduced TAS levels, CAT and GPx activities and GSH levels.

Correlated Product(s): Indomethacin sodium hydrate (HY-14397A)

Opposite Product(s): Carnosic acid (HY-N0644)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 53-86-1
Appearance Solid
Molecular Weight 357.79
Formula C₁₉H₁₆ClNO₄
Color White to off-white
SMILES

COC1=CC=C(N(C(C2=CC=C(Cl)C=C2)=O)C(C)=C3CC(O)=O)C3=C1
Synonyms

Indometacin
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (83)

All ELISAWBIFCell Proliferation/Viability AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Immunity

Alcaligenes faecalis induces intestinal T helper-17 cells by enhancing Rorc transcription through E3 ligase Trim21-mediated Fbxw7 degradation. [Abstract]

2025 Apr 8:S1074-7613(25)00128-1. PMID: 40215968
J Extracell Vesicles

CD7-targeting pro-apoptotic extracellular vesicles: A novel approach for T-cell haematological malignancy therapy. [Abstract]

2024 Dec;13(12):e70025. PMID: 39676736
J Extracell Vesicles

Proton pump inhibitors enhance macropinocytosis-mediated extracellular vesicle endocytosis by inducing membrane v-ATPase assembly. [Abstract]

2024 Apr;13(4):e12426. PMID: 38532609
Nat Commun

Platelet activation plays a pro-inflammatory role in myasthenia gravis. [Abstract]

2025 Oct 2;16(1):8779. PMID: 41038808
Hepatology

Eosinophils protect against acetaminophen-induced liver injury through cyclooxygenase-mediated IL-4/IL-13 production. [Abstract]

2023 Feb 1;77(2):456-465. PMID: 35714036

Indomethacin purchased from MedChemExpress. Usage Cited in: Hepatology. 2023 Feb 1;77(2):456-465. [Abstract]

WT BmEos was treated with IL-33 (20 ng/ml) in the presence or absence of indomethacin (50 μM) for 24 h. Protein levels of IL-4 and IL-13 in the supernatants were measured by ELISA.
J Adv Res

High-throughput screening identifies FDA approved drug mitiglinide as a novel pyroptosis inhibitor and therapeutic agent for osteoarthritis. [Abstract]

2025 Dec 11:S2090-1232(25)00994-4. PMID: 41386507
Genes Dis

2026 Jun 15.
Adv Sci (Weinh)

Exclusive Breastfeeding Drives AMPK-Dependent Thermogenic Memory in BAT and Promotes Long-Term Metabolic Benefits in Offspring. [Abstract]

2025 Dec 19:e08956. PMID: 41417620
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2025 Jan;12(4):e2410360. PMID: 39639496
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
Chem Eng J

2026 Mar 12.
Phytomedicine

Perillyl alcohol ameliorates high-fat diet-induced obesity in mice by modulating gut microbiota and activating IRF4-mediated brown fat thermogenesis. [Abstract]

2025 Nov 25:148:157400. PMID: 41138577
Phytomedicine

Tangeretin suppresses osteoarthritis progression via the Nrf2/NF-κB and MAPK/NF-κB signaling pathways. [Abstract]

2022 Apr:98:153928. PMID: 35104760
Phytomedicine

3'-Oxo-tabernaelegantine A (OTNA) selectively relaxes pulmonary arteries by inhibiting AhR. [Abstract]

2021 Nov:92:153751. PMID: 34563984
Adv Healthc Mater

Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention. [Abstract]

2026 Apr 30:e71198. PMID: 42059192
Int J Nanomedicine

A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer. [Abstract]

2020 May 1:15:3087-3098. PMID: 32431503
Antioxidants (Basel)

Discovery of Novel Pterostilbene Derivatives That Might Treat Sepsis by Attenuating Oxidative Stress and Inflammation through Modulation of MAPKs/NF-κB Signaling Pathways. [Abstract]

2021 Aug 24;10(9):1333. PMID: 34572964
Phytother Res

Poria cocos Polysaccharides Protect Against Contrast-Induced Renal Injury Through Activating CaMKK2/AMPK/PGC-1α Signaling Pathway. [Abstract]

2026 Jun 18. PMID: 42312878
Phytother Res

Gypenoside XVII Ameliorates Osteoarthritis and Suppresses Chondrocyte Apoptosis and Extracellular Matrix Degradation via STING-Dependent Inhibition of ER Stress. [Abstract]

2026 Apr 27. PMID: 42043276
Phytother Res

Daidzin Inhibits Endoplasmic Reticulum Stress by Regulating FoxO1 Expression to Alleviate Osteoarthritis Progression. [Abstract]

2025 Oct;39(10):4704-4717. PMID: 40889796
Clin Transl Med

Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma. [Abstract]

2021 Oct;11(10):e548. PMID: 34709754

Indomethacin purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]

ITGAV, ITGB3, p-FAK, FAK, p-PI3K, PI3K, p-AKT, AKT, p-GSK3β, and GSK3β protein levels were assessed in KYSE30 cells by Western blotting after treatment with DMSO or 200 µM Indomethacin (0–96 h).

Indomethacin purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]

HEK-293T cells were co-transfected with FLAG-ITGAV and HA-ubiquitin plasmids, pre-treated with MG132 for 12 h, and then incubated with indomethacin (200 µM) for 2 days.

Indomethacin purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]

KYSE30 and KYSE510 cells were treated with DMSO or Indomethacin for 24 h, followed by the detection of ITGAV protein levels using immunofluorescence.

Indomethacin purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]

ESCC cells were treated with DMSO or different concentrations of Indomethacin for various times (24, 48, or 96 h). Cell growth inhibition was detected by MTT assay.

Indomethacin purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]

PDX tumour size was plotted over 41 days (LEG74, n = 8/group), 26 days (LEG92, n = 12/group), or 13 days (LEG84, n = 10/group) to assess the effect of Indomethacin. Vehicle or indomethacin (1 or 4 mg/kg) was administered intra-gastrically. Tumour volumes were measured twice per week.
World J Gastroenterol

Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism. [Abstract]

2023 Oct 21;29(39):5452-5470. PMID: 37900995
Chin J Nat Med

Therapeutic effect of neohesperidin on TNF-α-stimulated human rheumatoid arthritis fibroblast-like synoviocytes. [Abstract]

2021 Oct;19(10):741-749. PMID: 34688464
Chin Med

Ajugol's upregulation of TFEB-mediated autophagy alleviates endoplasmic reticulum stress in chondrocytes and retards osteoarthritis progression in a mouse model. [Abstract]

2023 Sep 7;18(1):113. PMID: 37679844
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
Chem Mater

2017, 29(19):8221-8238.
Appl Mater Today

2023 Apr.
Pharmaceutics

Study on the Effect of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Baicalin in Cells Based on MRP2, MRP3, and BCRP Efflux Transporters. [Abstract]

2024 May 29;16(6):731. PMID: 38931853
J Ethnopharmacol

Lycopodium japonicum Thunb. inhibits chondrocyte apoptosis, senescence and inflammation in osteoarthritis through STING/NF-κB signaling pathway. [Abstract]

2024 Dec 5:335:118660. PMID: 39121926
Eur J Med Chem

Novel pterostilbene derivatives ameliorate heart failure by reducing oxidative stress and inflammation through regulating Nrf2/NF-κB signaling pathway. [Abstract]

2023 Oct 5:258:115602. PMID: 37406380
Eur J Med Chem

Design, synthesis, and SAR study of novel 4,5-dihydropyrazole-Thiazole derivatives with anti-inflammatory activities for the treatment of sepsis. [Abstract]

2021 Dec 5:225:113743. PMID: 34403978
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
Ecotoxicol Environ Saf

Effects of benzotriazoles UV-328, UV-329, and UV-P on the self-renewal and adipo-osteogenic differentiation of human mesenchymal stem cells. [Abstract]

2025 Jan 15:290:117765. PMID: 39847882
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Int Endod J

Integration of single-cell RNA sequencing of endothelial cells and proteomics to unravel the role of ICAM1-PTGS2 communication in apical periodontitis: A laboratory investigation. [Abstract]

2024 Sep;57(9):1228-1246. PMID: 38713190
Organogenesis

Tetramethylpyrazine Confers Protection Against Oxidative Stress and NLRP3-Dependent Pyroptosis in Rats with Endometriosis. [Abstract]

2025 Dec;21(1):2460261. PMID: 39967390
Inflammopharmacology

The sesquiterpene lactone components of Cichorium glandulosum suppress both in vitro and in vivo inflammatory responses by reducing IL-1β levels. [Abstract]

2025 Dec 2. PMID: 41329398
RSC Adv

Targeted delivery of gemcitabine to lung cancer cells via a hyaluronic acid-based nanoplatform. [Abstract]

2026 May 15;16(28):25944-25963. PMID: 42148272
Drug Des Devel Ther

Network Pharmacology and Experimental Validation Reveal Sishen Pill's Efficacy in Treating NSAID-Induced Small Intestinal Ulcers. [Abstract]

2025 Mar 19:19:2035-2050. PMID: 40124554
Cells

The Asp-Encoding Gene FBN1 Mediates Cold Adaptation in Sunite Sheep by Reprogramming Adipocyte Differentiation Towards Thermogenesis. [Abstract]

2026 Feb 11;15(4):329. PMID: 41744772
Int J Pharm

Predicting optimal wet granulation parameters for extrusion-spheronisation of pharmaceutical pellets using a mixer torque rheometer. [Abstract]

2017 Jan 30;517(1-2):19-24. PMID: 27915006
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Int Immunopharmacol

Oxyphenbutazone suppresses non-canonical inflammasome activation and protects against LPS-induced sepsis. [Abstract]

2026 Aug 15:183:116873. PMID: 42150290
ACS Appl Bio Mater

Feedback-Elevated Antitumor Amplifier of Self-Delivery Nanomedicine by Suppressing Photodynamic Therapy-Caused Inflammation. [Abstract]

2023 Jul 17;6(7):2816-2825. PMID: 37326439
Eur J Pharm Sci

Biophysical and docking study on the interaction of anticancer drugs encorafenib and binimetinib with human serum albumin. [Abstract]

2023 Oct 1:189:106550. PMID: 37527692
Bioorg Chem

Discovery of novel dihydropyrazole-stilbene derivatives for ameliorating heart failure through modulation of p38/NF-κB signaling pathway. [Abstract]

2022 Dec:129:106206. PMID: 36288667
Food Sci Nutr

Anti-Diabetic Effects of Ayanin, a Flavonoid Compound, in STZ/HFD-Induced Diabetic Mice by Upregulating GLUT4 and Suppressing Macrophage-Driven Inflammation in Adipose Tissues. [Abstract]

2026 Jan 7;14(1):e71429. PMID: 41509193
Mol Med Rep

Ghrelin promotes cardiomyocyte differentiation of adipose tissue‑derived mesenchymal stem cells by DDX17‑mediated regulation of the SFRP4/Wnt/β‑catenin axis. [Abstract]

2023 Sep;28(3):164. PMID: 37449526
J Lipid Res

KLF7 induced ADRB3-dependent IL-6 production in brown adipocytes during stress. [Abstract]

2026 Feb;67(2):100981. PMID: 41565113
Mol Pharm

Molecular Interactions of Cobimetinib and Vemurafenib with Human Serum Albumin: a Comparative Biophysical and Computational Analysis. [Abstract]

2025 Aug 4;22(8):4969-4982. PMID: 40662409
Metabolites

Intestinal Epithelial-Derived Exosomes Under Cold Stimulation Promote Adipose Thermogenesis. [Abstract]

2025 May 14;15(5):324. PMID: 40422900
Langmuir

Size Preferences Uptake of Glycosilica Nanoparticles to MDA-MB-231 Cell. [Abstract]

2020 Sep 29;36(38):11374-11382. PMID: 32902993
Front Physiol

Roles of Endothelial Motilin Receptor and Its Signal Transduction Pathway in Motilin-Induced Left Gastric Artery Relaxation in Dogs. [Abstract]

2021 Oct 28;12:770430. PMID: 34777026
Am J Physiol Endocrinol Metab

Glycogen synthesis is required for adaptive thermogenesis in beige adipose tissue and affects diet-induced obesity. [Abstract]

2024 May 1;326(5):E696-E708. PMID: 38568151
BMC Cancer

PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. [Abstract]

2019 Dec 2;19(1):1166. PMID: 31791289
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
Biochim Biophys Acta Mol Cell Biol Lipids

Partial inhibition of adipose CIDEC improves insulin sensitivity and increases energy expenditure in high-fat diet-fed mice via activating ATGL-PPARα pathway. [Abstract]

2025 Jul 7;1870(6):159659. PMID: 40633832
Cell Transplant

Adipose-derived stem cells inhibit dendritic cell migration by secreting tumor necrosis factor-α-stimulated gene 6 to improve the allogeneic skin transplantation survival rate in mice. [Abstract]

2025 Jan-Dec:34:9636897251376125. PMID: 41108126
Int J Med Sci

Integrated Phenotypic and Transcriptomic Analyses of Osteoporosis in Type 2 Diabetic Mice. [Abstract]

2025 Mar 10;22(8):1773-1790. PMID: 40225857
Drug Metab Dispos

Application of acoustic ejection mass spectrometry for plasma protein binding assay using flux dialysis. [Abstract]

2025 Nov 10;53(12):100200. PMID: 41386030
Toxicol Appl Pharmacol

The role of cPLA2 in Methylglyoxal-induced cell apoptosis of HUVECs. [Abstract]

2017 May 15:323:44-52. PMID: 28341536
Immun Inflamm Dis

Limonin ameliorates indomethacin-induced intestinal damage and ulcers through Nrf2/ARE pathway. [Abstract]

2023 Feb;11(2):e787. PMID: 36840501
Andrology

Cellular mechanism underlying leptin-induced anion secretion of rat epididymal epithelial cells. [Abstract]

2025 Feb;13(2):371-381. PMID: 38778669
J Therm Biol

Differential expression of ADRB1 causes different responses to norepinephrine in adipocytes of Duroc-Landrace-Yorkshire pigs and min pigs. [Abstract]

2024 Jul:123:103906. PMID: 38970835
J Appl Toxicol

Differential impacts of nonsteroidal anti-inflammatory drugs on lifespan and healthspan in aged Caenorhabditis elegans. [Abstract]

2024 Oct;44(10):1528-1539. PMID: 38840409
BMC Nephrol

Sodium selenite attenuates inflammatory response and oxidative stress injury by regulating the Nrf2/ARE pathway in contrast-induced acute kidney injury in rats. [Abstract]

2024 Jul 15;25(1):226. PMID: 39009991
Biomed Res Int

Gentiopicroside Produces Endothelium-Independent Vasodilation by Deactivating the PI3K/Akt/Rho-Kinase Pathway in Isolated Rat Thoracic Aorta. [Abstract]

2021 May 14:2021:5565748. PMID: 34095301
FEBS Open Bio

Anti-inflammatory properties of ophioglonin derived from the fern Ophioglossum vulgatum L. via inactivating NF-κB and MAPK signaling pathways. [Abstract]

2025 Jan;15(1):122-139. PMID: 39455284
Clin Exp Pharmacol Physiol

Indole-3-Propionic Acid Improves Vascular Function in High-Fat Diet-Induced Obese Mice via eNOS. [Abstract]

2025 Nov;52(11):e70081. PMID: 41057979
Biochem Biophys Res Commun

The synergistic administration of sanguinarine and curcumin ameliorates indomethacin-induced small intestinal injury in rats through the modulation of Nrf2 and NF-κB signaling pathways. [Abstract]

2025 Sep 25:781:152551. PMID: 40885044
Biochem Biophys Res Commun

Exosomes derived from human umbilical cord mesenchymal stem cells can reverse ventricular remodeling and improve long-term cardiac function after acute myocardial infarction. [Abstract]

2025 Jul 1:768:151920. PMID: 40327908
J Mol Liq

2026 May 23;457:129686.
Thai Journal of Pharmaceutical Sciences

2025 Dec.
Res Sq

2025 Nov 12.
Res Sq

2025 Oct 27.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

A genetically encoded fluorescent sensor for monitoring spatiotemporal prostaglandin E2 dynamics in vivo. [Abstract]

2025 Jun 3:2025.06.01.657218. PMID: 40501671
SSRN

2025 Mar 31.
bioRxiv

2024 Nov 08.
Front Med (Lausanne)

Erythropoietin Attenuates Experimental Contrast-Induced Nephrology: A Role for the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway. [Abstract]

2021 Apr 13:8:634882. PMID: 33928100
Eur Rev Med Pharmacol Sci

MSCs reduce airway remodeling in the lungs of asthmatic rats through the Wnt/β-catenin signaling pathway. [Abstract]

2020 Nov;24(21):11199-11211. PMID: 33215438
Research Square Preprint

2020 Oct.
Patent

US20180263995A1.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (279.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 12.5 mg/mL (34.94 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7949 mL

13.9747 mL

27.9494 mL

5 mM

0.5590 mL

2.7949 mL

5.5899 mL

10 mM

0.2795 mL

1.3975 mL

2.7949 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.49 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [Content Brief]

[2]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565-71. [Content Brief]

[3]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404. [Content Brief]

[4]. Helleberg L, et, al. Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981 Jul-Aug;6(4):245-58. [Content Brief]

[5]. Sabiu S, et, al. Indomethacin-induced gastric ulceration in rats: Protective roles of Spondias mombin a nd Ficus exasperate. Toxicol Rep. 2015 Jan 8:2:261-267. [Content Brief]

[6]. Danisman B, et, al, Carnosic Acid Ameliorates Indomethacin-Induced Gastric Ulceration in Rats by Alleviating Oxidative Stress and Inflammation. Biomedicines. 2023 Mar 9;11(3):829. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.7949 mL	13.9747 mL	27.9494 mL	69.8734 mL
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL	13.9747 mL
	10 mM	0.2795 mL	1.3975 mL	2.7949 mL	6.9873 mL
	15 mM	0.1863 mL	0.9316 mL	1.8633 mL	4.6582 mL
	20 mM	0.1397 mL	0.6987 mL	1.3975 mL	3.4937 mL
	25 mM	0.1118 mL	0.5590 mL	1.1180 mL	2.7949 mL
	30 mM	0.0932 mL	0.4658 mL	0.9316 mL	2.3291 mL
DMSO	40 mM	0.0699 mL	0.3494 mL	0.6987 mL	1.7468 mL
	50 mM	0.0559 mL	0.2795 mL	0.5590 mL	1.3975 mL
	60 mM	0.0466 mL	0.2329 mL	0.4658 mL	1.1646 mL
	80 mM	0.0349 mL	0.1747 mL	0.3494 mL	0.8734 mL
	100 mM	0.0279 mL	0.1397 mL	0.2795 mL	0.6987 mL

Keywords

Indomethacin

83 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Indomethacin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Animal Disease Model Inducer Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Indomethacin

All COX Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (83)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Indomethacin Related Classifications

HY-14397 Related Classifications